Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT04275323

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04275323
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04275323. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-02 (actual); primary completion 2024-06-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)
Condition
Arterial Occlusive Disease
Condition
Ischemia
Condition
Ulcers
Condition
Peripheral Vascular Disease
Intervention (Genetic)
NL003
Intervention (Other)
Normal Saline
Lead sponsor
Beijing Northland Biotech. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04275323
Content hash
7446e8b8f86a74eec5de27f4d6ce8db51371d6e776adb696cc8bcde2514fd145